European Journal of Clinical Pharmacology

, Volume 31, Issue 5, pp 613–615 | Cite as

Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine

  • B. Gachályi
  • Á. Vas
  • K. Csillag
  • B. Nagy
  • F. Kocsis
  • A. Káldor
Short Communications

Summary

The relationship between acetylator phenotype and the inhibitory effect of cimetidine on the hepatic metabolism of antipyrine has been studied in 20 subjects. Cimetidine, 1,0 g/day resulted in a significant decrease in the metabolic clearance rate of antipyrine, but only in slow acetylators, as fast acetylators were less affected. No sex difference was observed. No major change occurred in the urinary excretion of D-glucaric acid, which means that cimetidine had not-affected that Phase II reaction. It did significantly decrease the urinary partial clearance rate of norantipyrine, leaving that of antipyrine and 4-OH-antipyrine unchanged, which suggests that cimetidine had preferentially inhibited the P 450 isozyme that catalyses norantipyrine formation.

Key words

cimetidine antipyrine acetylator phenotypes microsomal inhibition 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rendic S, Sunjic V, Toso R, Kajfez F, Ruf HH (1979) Interaction of cimetidine with liver microsomes. Xenobiotica 9: 555–564Google Scholar
  2. 2.
    Feely J, Wilkinson GR, Wood AJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695Google Scholar
  3. 3.
    Somogyi A, Gugler R (1982) Drug interactions with cimetidine. Clin Pharmacokinet 7: 23–41Google Scholar
  4. 4.
    Feely J, Perira L, Guy E, Hockings N (1984) Factors affecting the response to inhibition of drug metabolism by cimetidine — dose response and sensitivity of elderly and induced subjects. Br J Clin Pharmacol 17: 77–81Google Scholar
  5. 5.
    Teunissen MWE, van Graft M, Vermeulen NPE, Breimer DD (1983) Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. Xenobiotica 13: 497–502Google Scholar
  6. 6.
    Teunissen MWE, Meerburg van der Torren JE, Vermeulen NPE, Breimer DD (1983) Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4′-dihydroxy-antipyrine. J Chromatogr 278: 367–378Google Scholar
  7. 7.
    Marsh CA (1960) Metabolism of D-glucuronolactone in mammalian systems. Biochem J 86: 77–86Google Scholar
  8. 8.
    Bratton AC, Marshall EK (1939) A new coupling component for sulfanilamide determination. J Biol Chem 128: 537–550Google Scholar
  9. 9.
    Gachályi B, Vas Á, Hajós P, Káldor A (1984) Acetylator phen otypes: Effect of age. Eur J Clin Pharmacol 26: 43–45Google Scholar
  10. 10.
    Puurunen J, Sotainemi E, Pelkonen O (1980) Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol 18: 185–187Google Scholar
  11. 11.
    Wilkinson CF, Hetnarski K, Hicks LJ (1974) Substituted imidazoles as inhibitors of microsomal oxidation and insecticide synergists. Pesticide Biochem Physiol 4: 299–312Google Scholar
  12. 12.
    Speeg KV, Patwardhan RV, Avant GR, Mitchell MC, Schenker S (1982) Inhibition of microsomal drug metabolism by histamine H 2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 82: 89–96Google Scholar
  13. 13.
    Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF (1984) The influence of cimetdine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 18: 421–430Google Scholar
  14. 14.
    Larousse C, LeNormand Y, Kergueris MF, Veyrac MJ, Chailleux E, Ordronnean J, Moigretean C (1980) Tuberculosis therapy and enzyme induction in man. Int J Clin Pharmacol Ther Toxicol 18: 163–168Google Scholar
  15. 15.
    Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, Stevenson JC, MacIntyre I, Park BK (1982) Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther 32: 525–530Google Scholar
  16. 16.
    Bruguerolle B (1986) Modifications de la pharmacocinétique des médicaments au cours du cycle menstruel. Therapie 41: 11–17Google Scholar
  17. 17.
    Vesell ES (1979) The antipyrine test in clinical pharmacology — conceptions and misconceptions. Clin Pharmacol Ther 26: 275–286Google Scholar
  18. 18.
    Slusher LB, Vesell ES (1984) Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites. Clin Pharmacol Ther 35: 568–575Google Scholar
  19. 19.
    Penno MB, Vesell ES (1983) Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. J Clin Invest 71: 1698–1709Google Scholar
  20. 20.
    Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15: 443–450Google Scholar
  21. 21.
    Roots I (1982) Genetische Ursachen für die Variabilität der Wirkungen und Nebenwirkungen von Arzneimitteln. Internist 23: 601–609Google Scholar
  22. 22.
    Eichelbaum M, Bertilsson L, Saewe J (1983) Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol 15: 317–321Google Scholar
  23. 23.
    Park BK (1982) Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol 14: 631–651Google Scholar
  24. 24.
    Danhof M, Teunissen MWE (1984) Antipyrine as a model drug to assess oxidative drug metabolizing activity in man. Pharm Int 5: 11–15Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • B. Gachályi
    • 1
  • Á. Vas
    • 1
  • K. Csillag
    • 1
  • B. Nagy
    • 2
  • F. Kocsis
    • 2
  • A. Káldor
    • 1
  1. 1.Department of MedicinePostgraduate Medical SchoolBudapestHungary
  2. 2.Visegrád Hospital of the City Council of BudapestBudapestHungary

Personalised recommendations